Introducing Alnylam Assist™

Alnylam Assist offers a wide range of services to guide your patients through treatment with ONPATTRO.

After a completed Start Form is submitted to Alnylam Assist, your patient will receive a dedicated Case Manager that can help with:

  • Benefit verification

  • Education on the prior authorizations, claims, and appeals processes

  • Financial assistance program enrollment for eligible patientsa

  • Disease and product education

  • Facilitation of product orders

To get started with ONPATTRO:

  1. Together with your patient, complete the Alnylam Assist™ Start Form, available at

  2. Start Forms can be submitted electronically or printed and faxed to 1-833-256-2747.

aPatients must meet specified financial and insurance eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

    • Important Safety Information


Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

  • Reduced Serum Vitamin A Levels and Recommended Supplementation

    ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

    Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

  • Adverse Reactions

    The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion‑related reactions (19%).

  • Indication

    ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

  • For additional information about ONPATTRO, please see the full Prescribing Information.